Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)
Version of Record online: 12 OCT 2013
© 2013 The Authors. The Journal of Clinical Pharmacology Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
The Journal of Clinical Pharmacology
Volume 54, Issue 1, pages 109–119, January 2014
How to Cite
Ohta, S., Tsuru, T., Terao, K., Mogi, S., Suzaki, M., Shono, E., Ishida, Y., Tarumi, E. and Imai, M. (2014), Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). Journal of Clinical Pharma, 54: 109–119. doi: 10.1002/jcph.185
- Issue online: 2 JAN 2014
- Version of Record online: 12 OCT 2013
- Accepted manuscript online: 30 SEP 2013 09:06AM EST
- Manuscript Accepted: 14 SEP 2013
- Manuscript Received: 14 MAY 2013
- 4Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and castleman disease. Blood. 2008; 112(10):3959–3964., , , , ,
- 15IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008; 67(11):1516–1523., , , et al.
- 17Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008; 58(10):2968–2980., , , et al.
- 18Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011; 63(3):609–621., , , et al.
- 20Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009; 19(1):12–19., , , et al.
- 21Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007; 66(9):1162–1167., , , et al.
- 34Pharmaceuticals and Medical Devices Agency Report of Deliberation Results for Actemra. 2008. http://www.pmda.go.jp/english/service/pdf/actemra.pdf